Interaction between blood pressure, lipoproteins, angiotensin, and vascular disease.
Chobanian
Aram V
AV
Boston University School of Medicine, 715 Albany Street, Boston, MA 02118, USA. achob@bu.edu
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000809:Angiotensins / Q000187:drug effects / Q000378:metabolism*; D000818:Animals; D001158:Arteries / Q000737:chemistry / Q000187:drug effects / Q000473:pathology; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008077:Lipoproteins, LDL / Q000187:drug effects / Q000378:metabolism*; D011725:Pyridines / Q000627:therapeutic use; D044140:Receptor, Angiotensin, Type 1; D011945:Receptors, Angiotensin / Q000627:therapeutic use; D012307:Risk Factors; D014652:Vascular Diseases / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology*
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000809:Angiotensins; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008077:Lipoproteins, LDL; D011725:Pyridines; D044140:Receptor, Angiotensin, Type 1; D011945:Receptors, Angiotensin; C086276:cerivastatin